Hydroxychloroquine has been shown to inhibit replication of SARS-CoV-2 in vitro. The
presented multicenter parallel-group open-label randomized clinical trial aims to investigate
the efficacy of prophylactic hydroxychloroquine on mitigation of risk of hospitalization due
to COVID-19 in patients with end-stage renal disease.